Terminal / Growth Hormone

Tesamorelin

Approved

aka Egrifta

Approved GHRH analog, specifically for shifting visceral belly fat.

Mechanism

A stabilised GHRH analog that raises GH and IGF-1. It got approved for one narrow job, cutting the deep visceral fat that builds up in HIV-associated lipodystrophy, and it's good at it.

Regulatory & Safety Status

Approved as Egrifta for HIV-associated lipodystrophy. Prescription drug. Everything else people run it for is off-label.

Research

2026JBJS reviews

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications

2026Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists

2026Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Selected Industry Highlights From IDWeek 2025

2026International journal of molecular sciences

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives

2024PubMed

Latest tesamorelin research

Related Compounds

Growth Hormone

Sermorelin

Research compound

GHRH analog that nudges your own pituitary to make GH. The gentle option.

Growth Hormone

CJC-1295

Research compound

Long-acting GHRH analog. The usual partner for ipamorelin.